Published within
| Type |
Product title / description
|
Pub
|
Price |
Report
|
An overview of M&A trends for the top 150 global pharmaceutical companies during 2008 and 2009 with discussion of the drivers of recent deals, plus case study analysis of key M&As.
Published By Datamonitor
|
17 Dec 2009 |
$11400
|
Report
|
China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis, but little is known about therapy dynamics and drivers of treatment choice. Particularly in China, a high emphasis on efficacy as well as cost leads to continued use of inexpensive, but suboptimal treatment approaches. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of patients numbers, frequently prescribed regimens and brand perceptions.
Published By Datamonitor
|
15 Feb 2010 |
$15200
|
Report
|
This report explores key issues in the hepatitis B market across the seven major markets (US, Japan, France, Italy, Spain, UK) and Turkey. It provides a ten year sales forecast, in-depth assessment of key drugs, and an analysis of market dynamics.
Published By Datamonitor
|
29 Jul 2010 |
$15200
|
Report
|
This report provides an overview of research and development, manufacturing, outsourcing, and distribution trends, as well as infrastructure profiles for the leading pharmaceutical companies in Turkey.
Published By Datamonitor
|
29 Jun 2011 |
$1520
|
Report
|
Overview of the generics and biosimilars landscape including, regulatory issues, drivers and resistors to uptake, level of penetration, and key players operating in the market.
Published By Datamonitor
|
29 Jun 2011 |
$1520
|
Report
|
This report provides an overview of healthcare expenditure, the insurance and healthcare system, healthcare reforms, drug regulation and intellectual property, and drug pricing and reimbursement in Turkey.
Published By Datamonitor
|
01 Jul 2011 |
$1520
|
Report
|
Datamonitor’s report Orphan Drug Trends provides an overview of orphan drug regulations in the major pharmaceutical markets, including pricing and reimbursement issues and an analysis of Big Pharma’s growing interest in orphan drugs.
Published By Datamonitor
|
25 Nov 2011 |
$2800
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.